Abstract
Postpartum hemorrhage (PPH) is a leading cause of global maternal mortality, making effective management strategies essential. Tranexamic acid (TXA), an antifibrinolytic agent, has emerged as a significant adjuvant therapy, and this study aimed to synthesize recent evidence on its role in managing PPH and impacting maternal outcomes. An integrative literature review was conducted by searching the PubMed database for original studies and clinical trials published between 2022 and 2025. From the articles retrieved using terms including "Postpartum Hemorrhage", "Tranexamic Acid" and “Obstetric Bleeding”, 11 relevant studies were selected for analysis. The findings indicate that TXA effectively reduces mean blood loss, the incidence of severe PPH, and the need for additional uterotonics, with benefits being most pronounced in high-risk scenarios such as cesarean sections. Evidence for universal prophylactic use, however, remains inconsistent. Across the studies, TXA demonstrated a favorable safety profile with a low risk of adverse events like thromboembolism. In conclusion, TXA is a valuable and safe intervention for managing PPH, particularly in high-risk patients. While its routine prophylactic use requires further validation, the evidence supports its integration into risk-based clinical protocols to improve maternal safety.